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Abstract 27 
Feline calicivirus (FCV) infections are associated with oral ulceration, chronic 28 
stomatitis and a limping syndrome. Epizootic outbreaks of virulent systemic disease 29 
(VSD) have been reported in the USA and Europe. Here, the molecular 30 
characterization and neutralization patterns of FCV isolates from cases of severe, 31 
non-epizootic infection associated with skin ulceration and edema are presented. 32 
Samples from eleven symptomatic cats, four in-contact cats and 27 cats with no 33 
contact with symptomatic cats were collected and tested for FCV, feline herpesvirus-34 
1 (FHV-1), feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV). 35 
Phylogenetic analyses based on the capsid (VP1) gene of FCV and virus 36 
neutralization with antisera raised against four FCV vaccine strains were performed. 37 
Nine kittens and two adult cats in two shelters and two veterinary clinics in four 38 
geographically distinct locations in Switzerland and Liechtenstein were affected. The 39 
cats showed fever, tongue and skin ulceration, head and paw edema, and 40 
occasionally jaundice, generalized edema and dyspnea. All symptomatic cats tested 41 
FCV-positive but were negative for FHV-1, FeLV and FIV, with the exception of one 42 
FIV-positive kitten. All kittens of one litter and both adult cats died. The disease did 43 
not spread to cats in the environment. Cats in the environment displayed 44 
phylogenetically distinct, but related, FCV strains. Virus neutralization patterns 45 
suggested that some cases might have been potentially prevented by vaccination 46 
with the optimal vaccine strain. In conclusion, clinicians should be aware of severe, 47 
non-epizootic forms of FCV infections with initial clinical presentations similar to VSD. 48 
Keywords: Feline calicivirus, virulent systemic disease, paw and mouth disease, 49 
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PCR, phylogenetic analysis, virus neutralization 50 
Introduction 51 
Feline calicivirus (FCV) is a highly infectious RNA virus of the family Caliciviridae and 52 
one of the most common viral pathogens in cats worldwide (Radford et al., 2009). 53 
The virus is detected in up to 40% of cats living in large groups (i.e. colonies or 54 
shelters) and in about 10% of privately owned cats living alone or in small groups 55 
(Bannasch and Foley, 2005; Coutts et al., 1994; Helps et al., 2005; Radford et al., 56 
2001; Wardley et al., 1974). FCV exhibits a remarkably high genetic evolution rate, 57 
which is thought to result from genetic drift or recombination (Coyne et al., 2006a; 58 
Coyne et al., 2007; Coyne et al., 2006c). Consequently, genetically diverse FCV 59 
isolates can be isolated amongst naturally infected cats (Coyne et al., 2012). It has 60 
been postulated that such genetic variation might favor the persistence of FCV in 61 
groups of cats, leading to the emergence of novel strains (Coyne et al., 2006a; 62 
Coyne et al., 2007; Coyne et al., 2006c).  63 
Typical of vesivirus infections, FCV has been associated with vesicular disease 64 
(Pesavento et al., 2008). Acute infections are characterized by transient fever and 65 
ulcerations on the tongue and palate of affected cats (Radford et al., 2009). In more 66 
severe cases, oral fauces, gingiva, lips and nasal philtrum may also be ulcerated. 67 
Another clinical presentation of FCV infection is the limping syndrome associated 68 
with transient lameness and acute synovitis (Radford et al., 2009). FCV has also 69 
been assigned to the feline upper respiratory tract disease (URTD) complex; 70 
however, classical signs of URTD in FCV-infected cats are often caused in 71 
conjunction with other viral or bacterial pathogens (Binns et al., 2000; Cai et al., 72 
2002; Helps et al., 2005), and not all FCV isolates induce respiratory disease 73 
following experimental challenge (Pesavento et al., 2008). FCV is also present in a 74 
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high proportion of cats displaying chronic lympho-plasmacytic gingivitis/stomatitis 75 
(Radford et al., 2009). This syndrome has so far not been successfully reproduced by 76 
experimental FCV infection (Knowles et al., 1991; Poulet et al., 2000) and is thought 77 
to represent an immune-mediated disease (Harley et al., 1999). In its most severe 78 
clinical form, FCV infection induces a highly contagious virulent systemic disease 79 
(VSD), which is characterized by a systemic inflammatory response syndrome 80 
(Pedersen et al., 2000). The disease involves internal organs as well as skin and 81 
mucous membranes. Affected cats show edema and skin ulceration, mainly around 82 
the head and limbs, and occasionally jaundice, dyspnea and bleeding tendencies 83 
(Coyne et al., 2006b; Pedersen et al., 2000; Radford et al., 2009; Schorr-Evans et al., 84 
2003; Schulz et al., 2011). Epizootic outbreaks of VSD were first reported in cats in 85 
North America, but subsequently also in Europe (Coyne et al., 2006b; Hurley et al., 86 
2004; Pedersen et al., 2000; Reynolds et al., 2009; Schorr-Evans et al., 2003; Schulz 87 
et al., 2011). The outbreaks usually occur in multi-cat environments and have been 88 
characterized by rapid onset and spread and high mortality (Radford et al., 2009). 89 
Published data suggest that these highly virulent strains emerge independently from 90 
genetically distinct FCV strains (Coyne et al., 2006b; Ossiboff and Parker, 2007; 91 
Reynolds et al., 2009; Schulz et al., 2011), but attempts to identify genetic patterns 92 
within the viral genome that define the highly virulent FCV biotype have been 93 
inconclusive (Abd-Eldaim et al., 2005; Foley et al., 2006; Prikhodko et al., 2014; 94 
Rong et al., 2006). Controversial results have been published concerning the 95 
protective effect of FCV vaccination against VSD. Most naturally infected cats 96 
developed VSD despite regular vaccination (Hurley et al., 2004; Schorr-Evans et al., 97 
2003). However, experimental infection with a virulent-systemic FCV isolate resulted 98 
in a milder, self-limiting course in cats vaccinated with the FCV vaccine strain F9 99 
when compared to unvaccinated cats (Pedersen et al., 2000).  100 
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In 1972, Cooper and Sabine described a cat with paw edema, oral lesions and skin 101 
ulcerations and called the syndrome 'paw and mouth disease' (Cooper and Sabine, 102 
1972); FCV was isolated from tongue and paw lesions of the affected cat. The initial 103 
clinical presentation of this syndrome was similar to that reported as VSD, but the 104 
syndrome lacked high mortality, obvious organ involvement and epizootic disease 105 
spread. In the present case series, we report eleven cases of severe, non-epizootic 106 
forms of FCV infections associated with ulcerative lesions on the head and limbs and 107 
cutaneous edema that occurred in four unrelated geographic locations in Switzerland 108 
and Liechtenstein. The study describes clinical data from the cases and presents the 109 
molecular characterization and analysis of susceptibility to neutralization of the FCV 110 
isolates from the affected cats.  111 
Material and Methods 112 
Case definition, sample and data collection. Cases were included when they met 113 
the following criteria: 1) ulcerative lesions on the head and limbs and/or the presence 114 
of cutaneous edema; 2) the detection of FCV in oropharyngeal cytobrushes from the 115 
affected cats and, if available, in blood, skin lesions and organs; 3) the exclusion of 116 
FHV-1 infection; and 4) the isolation of a similar FCV isolate (> 99% nucleotide 117 
identity in a 1616 bp fragment of the ORF2) amongst the cats if several cats were 118 
affected. A total of eleven symptomatic cats from four different locations in 119 
Switzerland and Liechtenstein were included and signalment, vaccination status and 120 
clinical signs were recorded. Samples were collected as indicated in Table 1. In 121 
addition, an oropharyngeal cytobrush from the queen and three cats in contact with 122 
the affected litter in shelter 1 and from 27 cats with no direct contact to the affected 123 
litter in shelter 1 were obtained. In shelter 2, samples were collected from case 7 at 124 
the time of disease and from cases 7 and 8 two months later (Table 1). Only the 125 
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latter samples were available for virus neutralization assays and phylogenetic 126 
analyses (see below).  127 
Sample processing and nucleic acid extraction. Oropharyngeal cytobrushes and 128 
swabs from cases 7 to 11 were collected into 300 μl of sterile viral transport medium. 129 
The medium consisted of 200 ml bi-distilled sterile water, 4 ml HEPES-Buffer 1 M 130 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany),   25  ml   Dulbecco’s   MEM   10x  131 
(Biochrom, Berlin, Germany), 25 ml heat inactivated fetal calf serum (FCS, Charge 132 
DO2303P, Origin South America, Bio Concept, Allschwil, Switzerland), 3 ml 100 x 133 
Antibiotic-Antimycotic (Gibco, Life Technologies, Lucerne, Switzerland) and 4 ml 134 
sodium hydrogen bicarbonate 7.5% (Merck, Darmstadt, Germany) at a pH of 7 that 135 
was adjusted using 1 M sodium hydroxide (Merck). Samples were stored at 4°C prior 136 
to shipping to the laboratory by priority mail and were processed within 96 h after 137 
collection. The samples from cases 1 to 6 were collected without viral transport 138 
medium; 300   μl of sterile phosphate buffered saline (PBS) were added to these 139 
samples upon arrival at the laboratory and the samples were processed within 12 h 140 
after collection. All cytobrushes/swabs were incubated for 10 min at 40°C and then 141 
turned upside down and centrifuged for 1 min at 6,440 x g. For cases 1 to 6, 100 μl of 142 
the supernatant from the oropharyngeal cytobrush were used for virus isolation (see 143 
below) and 200 μl were used for total nucleic acid (TNA) extraction. For cases 7 to 144 
11, supernatants from the oropharyngeal cytobrush and the nasal and conjunctival 145 
swabs were pooled and 400 μl used for virus isolation and 2 x 200 μl for TNA 146 
extraction. TNA extraction was performed from 200 μl of the oropharyngeal 147 
cytobrush, conjunctival and nasal swab supernatant, 200 μl of cell culture 148 
supernatant and from 100 μl of EDTA blood with the MagNa Pure LC (Roche 149 
Diagnostics AG, Rotkreuz, Switzerland) using the MagNa Pure LC TNA Isolation Kit 150 
(Roche Diagnostics AG). RNA from tissue samples was extracted with the Qiagen 151 
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RNeasy® mini Kit (Qiagen, Hombrechtikon, Switzerland). In each batch of 152 
extractions, a negative control was used to monitor for cross-contamination. 153 
Extracted nucleic acids were stored at -20°C until PCR analysis. 154 
Histology, immunohistochemistry and transmission electron microscopy. 155 
Cases 6 and 11 were examined post mortem and histology, immunohistochemistry 156 
(IHC) for feline herpesvirus-1 (FHV-1, performed in cases 6 and 11) and feline/canine 157 
parvovirus (performed in case 11) and transmission electron microscopy (TEM, 158 
performed in case 6) were conducted at the Institute of Veterinary Pathology, 159 
University of Zurich, Switzerland. The IHC for FCV (performed in case 11) was 160 
conducted by the Veterinary Laboratory Services, University of Liverpool, England. 161 
Samples for histological examination were collected from several skin locations, lung, 162 
liver, kidney, heart, pancreas and spleen; from case 11 samples were also collected 163 
from the oral mucosae, gut and mesenteric lymph node. All tissue samples were 164 
fixed in 4% neutral buffered formalin for 24 h, routinely processed for paraffin 165 
embedding, sectioned to prepare 2 - 3 µm thin sections and stained with hematoxylin 166 
and eosin (HE) and Periodic acid Schiff (PAS). The IHC for FCV was conducted on 167 
sections of skin, liver, spleen, lung, kidney and pancreas from case 11 according to 168 
published methods (Coyne et al., 2006b). Skin samples from cases 6 and 11 were 169 
examined immunohistochemically for FHV-1 according to published methods (Suchy 170 
et al., 2000). The IHC for feline/canine parvovirus was performed on gut samples 171 
from case 11 using a monoclonal anti feline/canine parvovirus antibody (MC2064, 172 
AbD Serotec, Puchheim, Germany). For TEM, tissue was dewaxed and refixed in 173 
2.5% glutaraldehyde followed by osmium tetroxide fixation and processed using 174 
routine protocols. 175 
Hematology and blood biochemistry. Hematology and blood biochemistry were 176 
performed in cases 1 to 6 and 11 at the Clinical Laboratory, Vetsuisse Faculty, 177 
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University of Zurich, on a Sysmex XT-2000iV (Sysmex Corporation, Kobe, Japan) 178 
(Weissenbacher et al., 2011) and Cobas Integra 800 instrument (Roche Diagnostics 179 
AG). The laboratory's own reference intervals were used for the adult cats and 180 
published reference intervals were used for the kittens (Meyers-Wallen et al., 1984).  181 
Virus isolation, titration and neutralization. For virus isolation, samples were 182 
filtered (Filtropur S 0.45 µm syringe filter, Sarstedt, Nümbrecht, Germany), incubated 183 
on 80% confluent Crandell-Rees feline kidney (CRFK) cells on 24-well plates (TPP 184 
Tissue Culture Testplate 24, TPP Techno Plastic Products AG, Trasadingen 185 
Switzerland) and cultured using RPMI 1640 Medium (Sigma-Aldrich) supplemented 186 
with 10% heat inactivated fetal calf serum (FCS, Invitrogen, Basel, Switzerland), 2 187 
mM L-glutamine (Gibco, Life Technologies) and 1x antibiotic-antimycotic (Gibco, Life 188 
Technologies). For each sample culture, a negative medium-only control was run in 189 
parallel. The samples were incubated on cells for two hours before 300 µl of 190 
complete medium were added. The cells were fed daily and evaluated for the 191 
presence of a cytopathic effect (CPE). If either a CPE was visible, or after a 192 
maximum of 7 days, the supernatant was collected for TNA extraction and stored at -193 
80°C until required for virus neutralization. Prior to virus neutralization, the FCV 194 
isolates were expanded using 2 x 105 cells/ml of feline embryo A (FEA) cells (Jarrett 195 
et al., 1973). Virus neutralization assays were performed on the isolates using the 196 
method described previously (Addie et al., 2008). Virus isolates were tested for 197 
neutralization against a panel of eight antisera raised in four pairs of cats infected 198 
once by the oronasal route with 1 ml of a viral suspension containing 106 TCID50 of 199 
FCV-F9, FCV-255, FCV-G1 or FCV-431 (one pair of cats was infected with each 200 
strain). The end point was calculated as the reciprocal of the highest serum dilution 201 
that showed CPE in no more than two of four wells. Similarly, the homologous titers 202 
of the antisera were calculated by testing them for neutralization against the relevant 203 
   Willi et al., 09.10.15 
 9 
FCV vaccine strain (FCV-F9, FCV-255, FCV-431 or FCV-G1). 204 
Diagnostic assays. For FCV testing, a previously described real-time TaqMan 205 
reverse transcription (RT)- quantitative (q)PCR assay was used (Helps et al., 2002). 206 
The assay was optimized prior to the start of the experiment. The reaction contained 207 
1 x One step RT-qPCR MasterMix Low ROX (Eurogentec, Seraing, Belgium), 300 208 
nM forward primer, 900 nM reverse primer, 250 nM probe, 5 µl nuclease-free water 209 
(Gibco, Life Technologies) and 0.125 µl Euroscript (Eurogentec). The temperature 210 
profile was 30 min at 48°C, followed by 10 min at 95°C and 45 cycles of 15 sec at 211 
95°C, followed by 1 min at 60°C. For the detection of FHV-1, a published real-time 212 
qPCR assay was used (Vogtlin et al., 2002). For feline leukemia virus (FeLV) and 213 
feline immunodeficiency virus (FIV) viral RNA detection in oropharyngeal 214 
cytobrushes (cases 7 to 10), previously described RT-qPCR assays were applied 215 
(Klein et al., 2001; Tandon et al., 2005). The real-time qPCR reactions were run on 216 
an ABI 7500Fast Real-Time PCR system (Applied Biosystems, Rotkreuz, 217 
Switzerland). Positive and negative controls were run with each assay. For FeLV p27 218 
antigen and FIV antibody detection, a published ELISA (cases 1 to 5 and 11) 219 
(Calzolari et al., 1995; Lutz et al., 1983) or a commercially available Snap Test (case 220 
7, FIV & FeLV Combi, Labor Laupeneck, Bern, Switzerland) was used.  221 
Capsid gene amplification and sequencing. The capsid (VP1) gene from a total of 222 
18 FCV isolates was sequenced using previously published primers (Primers AoA 223 
and AoS) that amplify 1945 nucleotides of the ORF 2 of FCV (Ohe et al., 2006). The 224 
FCV isolates derived from the eleven symptomatic cats (cases 1 to 11, Table 1), four 225 
in-contact cats in shelter 1 (queen and in-contact cats 1 to 3, Table 1) and three cats 226 
not in contact with symptomatic cats in shelter 1 (non-contact cats 1 to 3). RT-PCR 227 
and PCR amplification was performed with the SuperScript® III One-Step RT-PCR 228 
System with Platinum® Taq DNA Polymerase (Invitrogen) using standard cycling 229 
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conditions. PCR products were separated on a 1.5% agarose gel, and amplicons of 230 
the appropriate size were cut and purified using the GenEluteTM Gel Extraction Kit 231 
(Sigma-Aldrich). Direct sequencing of the purified amplicons was performed with the 232 
amplification primers (AoA, AoS) (Ohe et al., 2006) and with published (P1, P2) 233 
(Coyne et al., 2007) or   newly   designed   internal   primers   (S_FCV_FL.829f:   5’-CTA 234 
TCA CCT GAT GTC TGA TAC TGA - 3’;;  S_FCV_FL.1243r: 5’-CAC AAT AGA GTC 235 
GGT GGC AAT TCC A-3’;; S_FCV_FL.1265r: 5’-GCC AAC CAT CAG GTA TGC CT- 236 
3’; S_FCV_La.543f:  5’-GCT TGG TCT GGM TCT ATT GA- 3’; FCVSeq_6145_6164f: 237 
5’-CAY YTD ATG TCT GAY ACT GA-3’;;   FCVSeq_6705_6725r:   5’-GGR ATK GTD 238 
GTR TCD GGC CA-3’) at a commercial laboratory (Microsynth, Balgach, 239 
Switzerland) under standard conditions. 240 
Phylogenetic analyses. Nucleotide sequence editing, assembly and alignment were 241 
done using Geneious Version 7.1.7. Only the nucleotides available for all included 242 
sequences (1616 bp of the ORF2 of the capsid VP1 gene) were used to calculate 243 
nucleotide identities and for phylogenetic analyses. Amino acids were aligned using 244 
CLUSTAL W and BLOSUM cost matrix (Henikoff and Henikoff, 1992). The alignment 245 
was cut to 75 and 71 amino acids corresponding to residues 391 - 465 and 480 - 246 
550, respectively, on ORF2 for the reference sequence FCV-F9. Phylogenetic 247 
analysis was performed using CLUSTAL W (Thompson et al., 1994) and MEGA 248 
version 6. A phylogenetic tree was created by the Neighbor-Joining algorithm, using 249 
a distance matrix corrected for nucleotide substitutions based on the Tamura-Nei 250 
model and for amino acid substitution using the Poisson model. The dataset was re-251 
sampled 1,000 times to generate bootstrap values.  252 
Nucleotide sequence accession numbers. Nucleotide sequences have been 253 
submitted to GenBank under accession numbers KP862861 to KP 862878. 254 
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Results 255 
The eleven cases occurred between November 2011 and April 2014 in two shelters 256 
and two veterinary clinics in four geographically distinct locations in the two adjacent 257 
countries Switzerland and Liechtenstein.  258 
Cases 1 to 5 259 
Cases 1 to 5 occurred in November 2011 in shelter 1 in Schaan, Liechtenstein; these 260 
were five non-vaccinated three-month-old domestic shorthair (DSH) littermates. The 261 
kittens had been brought to the shelter two months before clinical signs occurred and 262 
were housed in a cage together with the queen (DSH, not vaccinated, age unknown). 263 
Three cats (in-contact cats 1 to 3, DSH, not vaccinated, 3 months, 4 months and 3 264 
years old, respectively) were located in a neighboring cage separated by a mesh; 265 
nose-to-nose contact could occur between the three in-contact cats and the 266 
symptomatic kittens. In-contact cat 2 entered the shelter 17 days before the first 267 
signs occurred in cases 1 to 5. The affected kittens showed apathy, anorexia, fever, 268 
salivation, edema of the paws and pinna, tongue ulcerations and skin ulcerations 269 
around the head and paws. The queen and the three in-contact cats showed no 270 
clinical signs. Cases 1 to 5 showed moderate anemia, lymphopenia and leukopenia, 271 
with a left shift in one kitten (data not shown). All affected kittens tested FCV-positive 272 
but were negative for FHV-1, FeLV and FIV (Table 1). FCV was detected in the 273 
queen and the three in-contact cats (Table 1) and in 7 of 27 cats (26%) kept outside 274 
the quarantine room in shelter 1; six of these latter cats were clinically healthy and 275 
one showed signs of URTD. Cases 1 to 5 were treated symptomatically with 276 
antibiotics (chloramphenicol and cefovecin) and non-steroidal anti-inflammatory 277 
drugs (meloxicam) and recovered within 10 days.  278 
   Willi et al., 09.10.15 
 12 
Case 6 279 
Case 6 was a vaccinated 10-year-old male castrated DSH cat without outdoor 280 
access that lived together with two other cats. Case 6 was brought into the small 281 
animal clinic of the Vetsuisse Faculty of the University of Zurich, Switzerland (clinic 1) 282 
in July of 2012 because of obstructive feline lower urinary tract disease. After 283 
unsuccessful conservative treatment, the cat received a perineal urethrostomy and 284 
was discharged with antibiotic (amoxicillin-clavulanic acid) and anti-inflammatory 285 
treatment (meloxicam). One day after discharge, the cat was presented again with 286 
apathy, fever and swollen paws. Within two days, the cat developed head oedema, 287 
tongue ulceration, skin pustules and ulcerations at the belly and around the anus 288 
(Supplementary Figure 1). The cat showed severe lymphopenia, left shift, moderate 289 
to severe hyperbilirubinemia, moderate hypoproteinemia, hypoalbuminemia and 290 
hyponatremia and slight hyperglycemia (data not shown). The cat tested FCV-291 
positive in the oropharyngeal cytobrush, as well as in blood, edema and pustule fluid, 292 
but tested negative for FHV-1 (Table 1). Despite symptomatic treatment with 293 
intravenous infusions, antibiotics (amoxicillin-clavulanic acid), pain medication 294 
(buprenorphine), anti-inflammatory drugs (meloxicam), antiemetics (ondansetron) 295 
and a proton pump inhibitor (esomeprazole), the clinical condition of the cat 296 
deteriorated. The cat was euthanized four days after the second presentation. At 297 
necropsy, the cat was icteric and had marked subcutaneous edema on the head and 298 
paws. Skin histology revealed prominent intraepidermal and suprabasal pustules 299 
filled with numerous degenerated neutrophils (Figure 1 a). The lesions extended to 300 
full-thickness necrosis of the epidermis or extended into the dermis, obscuring the 301 
dermal-epidermal junction. The hair follicular epithelium was also involved in the 302 
necrotizing process. In the liver, the hepatocytes showed fading nuclei and yellow 303 
intracytoplasmic pigmentation; some bile duct capillaries were congested by bile 304 
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plugs (intrahepatic cholestasis). There was a mild nonspecific periportal infiltration 305 
with neutrophils, lymphocytes and plasma cells. The hepatocytes were dissociated 306 
due to autolysis, but there was no evidence of necrosis or vasculitis. Pancreas and 307 
spleen were unremarkable. The evaluation of the intestine was reduced due to 308 
autolysis but a few crypt abscesses could be found.  309 
In TEM, intracytoplasmic paracrystalline virion arrays were detectable in a follicular 310 
adnexal epithelial cell (data not shown). IHC for FHV-1 in skin lesions was negative 311 
and IHC for FCV was not performed.  312 
Cases 7 and 8 313 
Cases 7 and 8 occurred in August 2012 in shelter 2 in Lausanne, Switzerland and 314 
involved four non-vaccinated two-month-old DSH kittens from one litter. The kittens 315 
had entered the shelter as newborn kittens two months before the first clinical signs 316 
occurred. Samples were collected from two kittens (cases 7 and 8) for the present 317 
study (Table 1). The kittens displayed apathy, fever, nasal discharge, and ulcers on 318 
the skin (muzzle, pinna and paws) and tongue. The kittens tested FCV-positive and 319 
negative for FHV-1, FeLV and FIV (Table 1). After symptomatic treatment with 320 
antibiotics (amoxicillin-clavulanic acid) and a non-steroidal anti-inflammatory drug 321 
(metamizole), the cats recovered within four to five days. 322 
Cases 9 and 10 323 
Cases 9 and 10 occurred five months later again in shelter 2 and involved a litter of 324 
three three-month-old DSH kittens that was born in the shelter. Samples were 325 
collected from two kittens (cases 9 and 10) for the present study (Table 1). The three 326 
kittens initially showed signs of apathy, anorexia and diarrhea, but recovered with 327 
symptomatic treatment with antibiotics and a spasmolytic drug. Three weeks after the 328 
first occurrence of clinical signs, the kittens were vaccinated against panleukopenia, 329 
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FCV and FHV-1 (Feligen®, Virbac, Glattbrugg, Switzerland). Two days later, one of 330 
the kittens was found dead. No samples were available from this animal. Ten days 331 
later, the other two kittens developed severe apathy, skin and lip ulceration, and 332 
edema of the pinna and front legs. Both kittens tested FCV-positive and one kitten 333 
tested positive for FIV-viremia (Table 1). Both cats were negative for FHV-1 and 334 
FeLV (Table 1). Despite symptomatic treatment with antibiotics (amoxicillin-clavulanic 335 
acid) and a non-steroidal anti-inflammatory drug (meloxicam), the clinical condition of 336 
the two kittens deteriorated and both cats developed dyspnea. Radiographic 337 
examination of the thorax of one of the kittens showed a generalized, severe 338 
interstitial to alveolar lung pattern with consolidation of the ventral lung lobes. 339 
Radiographs were compatible with pneumonia. One kitten died and the other was 340 
euthanized. No necropsies were performed. 341 
Case 11 342 
A vaccinated 10-year-old, male castrated DSH cat, kept as single cat with outdoor 343 
access, was brought into a small animal clinic in Oftrigen-Zofingen, Switzerland 344 
(clinic 2) in April 2014 with fever and a swollen paw. The cat received antibiotic 345 
(amoxicillin-clavulanic acid) and anti-inflammatory treatment (meloxicam) and was 346 
sent home. Two days later, the cat was presented again with fever and head and 347 
paw edema. Within three days, the cat developed generalized edema and severe 348 
jaundice. The cat showed a left shift and moderate lymphopenia, severe 349 
hyperbilirubinemia, hypoproteinemia and hypoalbuminemia, moderate hyponatremia 350 
and slight hyperglycemia. The cat tested FCV-positive in mucosal swabs and blood, 351 
and subsequently in biopsies of oral mucosa, skin and liver that were obtained post 352 
mortem (Table 1). Tests were negative for FHV-1, FeLV and FIV (Table 1). The 353 
antibiotic treatment was changed to fluoroquinolones and clindamycin and the cat 354 
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was treated symptomatically with intravenous infusions and an anti-inflammatory 355 
drug (meloxicam). Because the clinical condition continued to deteriorate, the cat 356 
was euthanized four days later. At necropsy, the cat was icteric and showed 357 
subcutaneous edema mainly on the fore limbs, around the knees, on the head, 358 
thorax and back. No ulcerative or pustular lesions were visible on the oral mucosa, 359 
the paws and on the haired skin. In skin histology, case 11 showed different degrees 360 
of epithelial necrosis, but the stratum corneum remained intact (Figure 1b). Liver 361 
histology revealed mild lipidosis and a slightly increased amount of lipidgranulomas; 362 
the yellow intrahepatocytic pigment could be identified as hemosiderin by Prussian 363 
blue staining. No histological lesions could be found in pancreas or spleen. There 364 
was mild peripancreatic fatty tissue necrosis that was interpreted as an artifact 365 
because of a lack of cellular reaction within the pancreas. The cat showed acute 366 
crypt cell necrosis in the jejunum and acute multifocal purulent and necrotizing colitis. 367 
The necrotizing colitis was associated to fungal infection with morphology of 368 
Aspergillus species. Fungal hyphae were not found in any other tissue of the cat. The 369 
IHC for feline/canine parvovirus performed on gut samples of case 11 was negative. 370 
The IHC for FCV demonstrated clusters of FCV-positive basal cells adjacent to 371 
degenerated cells and some FCV-positive cells in the liver and spleen (data not 372 
shown). The IHC for FHV-1 in skin lesions was negative.  373 
Genetic and phylogenetic analyses of FCV isolates 374 
From a total of 18 FCV isolates, 1,616 nucleotides of the ORF 2 encoding the capsid 375 
(VP1) protein of FCV were sequenced and phylogenetically analyzed (Figure 2). The 376 
FCV isolates from the different disease outbreaks were different from each other 377 
(74.3 - 82.6% nucleotide identity) as well as from published FCV isolates from VSD 378 
outbreaks (74.7 - 79.3% nucleotide identity when compared with FCV AY560117, 379 
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DQ91079, EU202915 and DQ910795).  380 
The FCV isolates from shelter 1 (from cases 1 to 5, from the queen and the three in-381 
contact cats) shared 99.5 - 99.9% nucleotide identity in the capsid (VP1) gene. The 382 
capsid (VP1) gene from the FCV isolates from cats kept outside the quarantine room 383 
in shelter 1 (non-contact cats 1 to 3) showed only moderate sequence identity (83.5 - 384 
84.0% nucleotide identity) with isolates from the affected kittens (cases 1 to 5), the 385 
queen and the three in-contact cats. Phylogenetic analysis revealed that the FCV 386 
isolates from the non-contact cats were phylogenetically related to but distinct from 387 
the isolates of the affected kittens (Figure 2).  388 
The FCV isolates from the two disease outbreaks that occurred in shelter 2 five 389 
months apart in two different litters (cases 7 to 8 and 9 to 10, respectively) appeared 390 
to be distinct (82.5 - 82.6% nucleotide identity, Figure 2). Of note, the isolates from 391 
cases 9 and 10 were clearly distinct from the vaccine strain FCV-F9 (M86379, 77.3 - 392 
77.4% nucleotide identity, Figure 2); FCV-F9 was the vaccine strain that these cats 393 
had received prior to the onset of disease. The FCV isolates from cases 6 and 11 394 
that occurred in clinic 1 and 2, respectively, were phylogenetically distinct from the 395 
other isolates in this study, as well as from published FCV isolates from VSD 396 
outbreaks (Figure 2).  397 
Comparative analysis of the amino acid sequences of the capsid VP1 region of the 398 
15 isolates did not reveal consistent substitutions in all FCV isolates of this study 399 
(Figure 3 a and b). The majority of substitutions clustered to region D and 400 
hypervariable region E of the capsid VP1 (Figure 3). Several amino acid changes 401 
were observed in residues known either to be associated with the selection of 402 
neutralization resistant virus mutants or to be part of linear B-cell epitopes (Figure 3 a 403 
and b)(Radford et al., 1999; Tohya et al., 1997). Some of the amino acid substitutions 404 
recently reported to be associated with VSD were also observed in the FCV isolates 405 
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from this study (V430T, N443S, G450D, D452E and V456M; Figure 3 a). Some of 406 
these substitutions were also present in published sequences from FCV isolates not 407 
associated with VSD (V430T, N443S, D452E; Figure 3 a). Other published 408 
substitutions were not evident in any of the FCV isolates in this study (E399K, 409 
T438V, A448K, D455M, K458S), and some residues displayed heterogeneous 410 
substitutions (E399K, A448K, G450D, D455M; Figure 3 a).  411 
When the amino acid sequences of the capsid VP 1 region were compared between 412 
the FCV isolates of the affected litter (cases 1 - 5), the FCV isolates of the queen and 413 
the three in-contact cats and the FCV isolates of cats with no contact with the 414 
affected litter in shelter 1 (non-contact cats 1 - 3), a total of 34 substitutions were 415 
found that were present in the isolates of the affected kittens and healthy in-contact 416 
cats and absent in the FCV isolates of the non-contact cats (Figure 3 b, and I101V, 417 
N120S, S128G, Q202D, A303T, S318A, K575R, I615V). Again, most substitutions 418 
clustered to region D and hypervariable region E of the capsid VP1 gene (Figure 3 419 
b).  420 
Virus neutralization of FCV isolates 421 
Thirteen FCV isolates from this study were tested by virus neutralization against eight 422 
antisera recognizing the common FCV vaccine strains (FCV-G1, FCV-431, FCV-255 423 
and FCV-F9, Table 2); no viruses were available for virus neutralization from case 2 424 
and the queen in shelter 1. FCV isolates from the same disease outbreak showed 425 
similar neutralization patterns, whereas virus neutralization patterns were clearly 426 
distinct between different disease outbreaks. FCV isolates from cases 6, 9 and 10 427 
showed low neutralization titers with all antisera tested. The homologous 428 
neutralization titers of the antisera S7 and S8 (FCV-F9) were three to nine times 429 
lower than the homologous titers of the antisera S1 to S6 (FCV-G1, FCV-431 and 430 
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FCV-255). The low to undetectable neutralization titers obtained with antisera S7 and 431 
S8 (FCV-F9) for the FCV isolates tested here could therefore be related to the lower 432 
potency of these antisera. Antisera raised against the same FCV vaccine strain in 433 
two different cats showed marked differences in the neutralization titers for the same 434 
FCV isolate (S1 and S2, S3 and S4, S5 and S6, respectively; Table 2). 435 
Discussion 436 
The present case series provides a clinical, histological and genetic characterization 437 
and analysis of virus neutralization patterns of severe, non-epizootic forms of FCV 438 
infections associated with head, paw or generalized edema and ulcerations on the 439 
head and limbs. The present cases had initial clinical presentations suspicious of 440 
VSD, but they lacked some characteristics that define the syndrome: namely some 441 
were missing inner organ involvement and high mortality and all were lacking 442 
epizootic disease spread (Radford et al., 2009).  443 
The clinical presentation and disease course in cases 1 to 5 in shelter 1 and cases 7 444 
to 8 in shelter 2 resembled the 'paw and mouth disease' syndrome described by 445 
Cooper and Sabine in 1972 (Cooper and Sabine, 1972). These kittens showed 446 
edema and/or skin ulcerations localized to the head and paws, but no signs of inner 447 
organ involvement or a systemic inflammatory response syndrome; all animals 448 
survived with supportive care. In contrast, the two adult cats (cases 6 and 11) and 449 
the kittens of the second outbreak in shelter 2 (cases 9 and 10) showed signs of a 450 
systemic inflammatory response syndrome and inner organ involvement, i.e. severe 451 
edema, left shift, icterus, hypoproteinemia (cases 6 and 11), dyspnea with 452 
radiographic signs of pneumonia (cases 9 and 10), intestinal crypt lesions (case 11) 453 
and the detection of FCV by IHC in the liver and spleen (case 11). These cases 454 
deteriorated quickly and died or were euthanized. Although the clinical presentations 455 
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and disease course in these cats resembled VSD, co-morbidities could have 456 
accounted for the severe outcome: case 6 had a prehistory of obstructive FLUTD and 457 
perineal urethrostomy, case 10 tested positive for FIV viremia, cases 9 and 10 had 458 
previously histories of diarrhea and case 11 showed signs of an intestinal fungal 459 
infection at necropsy. Furthermore, pancreatitis, pancreatic or hepatic necrosis, 460 
interstitial pneumonia or disseminated thrombosis which have been reported in cats 461 
with VSD (Hurley et al., 2004; Pedersen et al., 2000; Pesavento et al., 2004; Schorr-462 
Evans et al., 2003) were not found during the necropsies of cases 6 and 11, although 463 
the histological evaluation was hampered by euthanasia and some degree of 464 
autolysis. Intestinal crypt necrosis, as found in case 11, was described in cases of 465 
VSD (Pedersen et al., 2000; Schulz et al., 2011), but some of these cats were co-466 
infected with feline parvovirus. Case 11 tested negative for feline/canine parvovirus 467 
by IHC, but a fungal infection with morphology of Aspergillus species was detected in 468 
the colon; perhaps a consequence of the intense antibiotic therapy or terminal severe 469 
FCV infection with debilitation of the immune system (Pedersen et al., 2000). The 470 
present study suggests that severe forms of FCV infections can initially present 471 
similar to VSD, but high mortality and inner organ involvement is not always present, 472 
and disease severity might also depend on the immune status of the cat and 473 
aggravating factors, such as co-morbidities and crowding.  474 
Remarkably, one severely affected cat in the present study (case 11) showed 475 
generalized edema and icterus, but no macroscopic skin lesions or oral ulcerations 476 
up until the time of death. The lack of cutaneous or oral lesions in this cat was in 477 
accordance with the histological findings, which revealed an intact stratum corneum 478 
overlying marked epidermal degeneration. Hence FCV infection should be included 479 
in the differential diagnosis for any cat presenting with head, paw or generalized 480 
edema, even in the absence of macroscopic ulcerations of the skin or oral cavity.  481 
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Another defining criterion of VSD is epizootic disease spread. This was not noted in 482 
any of the present outbreaks. Whether this was due to the strict quarantine measures 483 
that had been implemented upon FCV diagnosis, or related to intrinsic properties of 484 
the FCV strains, remains unknown. There have been two recent reports of single 485 
cases of non-epizootic VSD (Battilani et al., 2013; Meyer et al., 2011). Battilani et al. 486 
described a FIV-positive cat with fever, oral ulceration, liver necrosis and multifocal 487 
hemorrhage (Battilani et al., 2013). Interestingly, the FCV strains isolated from the 488 
oropharyngeal cytobrush and internal organs of this cat showed only moderate 489 
sequence identity in the capsid (VP1) gene. The in-contact cats remained clinically 490 
healthy, but tested FCV-positive; the healthy in-contacts were infected with a 491 
genetically distinct FCV strain. In the study reported by Meyer et al., the affected cat 492 
showed subcutaneous edema and necrotizing dermatitis, but there was no necrosis 493 
of organs other than the skin and oral cavity and none of the other six cats in the 494 
same household developed disease despite close contact (Meyer et al., 2011); 495 
unfortunately, the in-contact cats were not tested for FCV infection.  496 
Similar to outbreaks of VSD (Battilani et al., 2013; Coyne et al., 2006b; Hurley et al., 497 
2004; Meyer et al., 2011; Pedersen et al., 2000; Reynolds et al., 2009; Schorr-Evans 498 
et al., 2003; Schulz et al., 2011), all but one of the disease outbreaks in this study 499 
(case 11) originated in multi-cat environments. The high genetic evolution of FCV 500 
and high levels of replication in large groups of cats provide the ideal conditions 501 
necessary for the emergence of highly virulent strains (Radford et al., 2009). 502 
Outbreaks of VSD often start with the introduction of cats from large rescue colonies 503 
into another multi-cat environment, such as a veterinary clinic or shelter (Radford et 504 
al., 2007). In the present cases, the origin of the infection was unknown. The kittens 505 
in shelter 1 (cases 1 to 5) were brought to the shelter two months before the first 506 
clinical signs occurred. However, one asymptomatic kitten in close contact with the 507 
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kittens (in-contact cat 2) and infected with a similar FCV isolate (> 99% nucleotide 508 
identity of the 1616 bp of ORF2) entered the shelter 17 days before the first signs in 509 
the affected kittens occurred. It could be speculated that this in-contact cat might 510 
have introduced the FCV infection to the kittens. Genetic and phylogenetic analyses 511 
of the FCV isolates from shelter 1 revealed that the isolates from cats kept outside 512 
the quarantine room (non-contact cats 1 to 3) were phylogenetically related to the 513 
isolates of the affected kittens (cases 1 to 5), the queen and the three non-affected 514 
in-contact cats. This suggests that the FCV isolate causing this severe disease 515 
manifestation in shelter 1 was not introduced; rather it had evolved de novo in the 516 
shelter environment. The fact that the in-contact cats in shelter 1 remained clinically 517 
healthy is remarkable, since two of the in-contact cats were young, unvaccinated 518 
kittens from a different litter. Age and immune status appear not to be the sole 519 
reason for the observed differences in susceptibility to FCV-induced disease.  520 
The kittens in shelter 2 were either born in the shelter (cases 9 and 10) or entered 521 
the shelter as newborn kittens (cases 7 and 8) two months before the first clinical 522 
signs occurred. These animals might have acquired infection in the shelter 523 
environment. Phylogenetic analyses revealed that the FCV strains from the two 524 
outbreaks in shelter 2 were distinct, suggesting that they were not directly transferred 525 
between the outbreaks. The FCV infection of case 6 might represent a nosocomial 526 
infection that had been acquired during the first hospitalization in clinic 1, although no 527 
cases with similar clinical signs were reported in clinic 1 in the weeks before or after 528 
case 6 was diagnosed. The infection source remained unresolved for case 11. This 529 
animal already showed paw edema when the cat was presented to the veterinary 530 
clinic; a nosocomial transmission therefore seems unlikely. The cat originated from a 531 
single cat household but had free access to the outdoors. 532 
So far, attempts to identify genetic markers unique to FCV strains that cause VSD 533 
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have been inconclusive (Abd-Eldaim et al., 2005; Foley et al., 2006; Prikhodko et al., 534 
2014; Rong et al., 2006). When we compared the amino acid sequences of the 535 
capsid VP1 region of the FCV isolates from this study to each other, no characteristic 536 
signatures could be identified. The genetic and phylogenetic analyses revealed that 537 
the FCV isolates causing these severe forms of disease were similar to other FCV 538 
strains and to VSD-associated strains. The isolates from different outbreaks were 539 
phylogenetically unrelated and showed extensive genetic variability. 540 
The kittens of one of the affected litters in shelter 2 (cases 9 and 10) had been 541 
vaccinated against FCV between two and ten days prior to the development of FCV-542 
associated disease. The private veterinarian therefore suspected that the clinical 543 
signs could have been caused by the vaccine strain. However, sequence analyses of 544 
the FCV isolates from these animals showed only 77.3 - 77.4% nucleotide identity 545 
with vaccine strain FCV-F9, which had been used to vaccinate the kittens. These 546 
findings imply that the temporal relationship between vaccination and the 547 
development of disease was a random coincidence, although vaccination might have 548 
influenced the disease course if the cats had a pre-existing infection with FCV.  549 
The four cats that died (cases 6 and 9 to 11) had been vaccinated against FCV, but 550 
three of them had only been incompletely vaccinated. The two kittens that died 551 
(cases 9 and 10) had received only one shot of FCV vaccine two days before the first 552 
kitten of the litter died (not included in the study) and 10 days before the first 553 
symptoms in kittens 9 and 10 occurred. One of the adult cats that died (case 6) had 554 
last received a FCV vaccine 3 years previously. Results of virus neutralization assays 555 
suggested that the cases in shelter 1 and clinic 2 and one of the outbreaks in shelter 556 
2 might have been potentially prevented by vaccination with the optimal vaccine 557 
strain. However, none of the antisera raised against four different vaccine strains 558 
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showed high cross-neutralization of all of the FCV isolates from this study, indicating 559 
that no single vaccine strain would have been predicted to protect against all 560 
outbreaks of disease reported in this study. Furthermore, antisera raised against the 561 
same FCV vaccine strain in different cats showed marked differences in the 562 
neutralization titers for the same FCV isolate, suggesting a remarkable individual 563 
variation in the immune response elicited to FCV. The fact that the antisera raised 564 
against the vaccine strain FCV-F9 showed low to undetectable neutralization titers 565 
with all FCV isolates from this study could be explained by the lower potency of the 566 
F9 antisera, as indicated by the low homologous antibody titers. Finally, serum 567 
neutralization might underestimate protection, since cell-mediated immune 568 
mechanisms are also thought to play a role in protection against FCV infection, 569 
particularly when modified live-virus vaccines are applied (Lesbros et al., 2013). 570 
Conclusions 571 
The present case series provides an extensive investigation of eleven cases of 572 
severe forms of FCV infections associated with edema and skin ulcerations. Most of 573 
the cases occurred in multi-cat environments and the cats presented with a spectrum 574 
of clinical signs and disease severity. The FCV isolates from the affected cats 575 
exhibited distinct genetic backgrounds and virus neutralization patterns. Disease 576 
severity appeared, on the one hand, to depend on intrinsic properties of the FCV 577 
isolate but, on the other hand, also on the susceptibility of the cats and on 578 
aggravating factors, such as co-morbidities or crowding. Our data suggest that 579 
severe forms of FCV infections can present initially with clinical signs similar to VSD, 580 
but high mortality and inner organ involvement is not always present and epizootic 581 
disease spread may be absent.  582 
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Figure captions 775 
Figure 1: Skin histology of case 6 and 11. a. Haired skin of the thigh, case 6: intraepidermal and 776 
suprabasal pustules (arrow) associated with full-thickness epidermal necrosis. Abrupt transition from 777 
normal to affected skin. Many perifollicular degenerating neutrophils in the superficial dermis (HE). b. 778 
Haired skin, paw, case 11. Segmental vacuolar degeneration of basal cells* to reticular degeneration 779 
also of stratum spinosum und stratum granulosum cells** to full thickness necrosis*** with still intact 780 
stratum corneum. Marked dermal edema with sparse inflammatory cells (HE). 781 
Figure 2: Phylogenetic analysis of 1,616 bp of ORF2 of FCV isolates of this study. A total of 18 782 
FCV isolates obtained within this study (in bold), 14 published FCV isolates reported in the USA, 783 
Japan, France, the UK, Germany and Australia and the vaccine strain FCV-F9 are shown. FCV 784 
isolates from VSD outbreaks are indicated with VS-FCV. Rabbit hemorrhagic fever virus (RHD) was 785 
used as an outlier. GenBank accession numbers are shown in parentheses. The scale bar indicates 786 
the number of estimated nucleotide substitutions per site. Only bootstrap values above 70% are 787 
shown. The sequences derived from the following cases: case 6 (clinic 1), cases 7 to 10 (shelter 2), 788 
case 11 (clinic 2), cases 1 to 5 (shelter 1); and from the queen and three in-contact cats, as well as 789 
from three cats without contact with the affected kittens in shelter 1 (non-contact cats 1 to 3). TNA 790 
extracted from oropharyngeal cytobrush was used for sequencing for all cats except for case 5, the 791 
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queen and in-contact cats 1 and 2 for which TNA extracted from cell culture supernatant was used. In 792 
addition, for cases 6 and 11, TNA extracted from blood was used for sequencing; the sequences from 793 
oropharyngeal cytobrush and blood from the same cat showed > 99% sequence identity (data not 794 
shown). 795 
Figure 3: Alignment of the capsid VP1 amino acid sequence of FCV isolates of this study. a. 796 
Residues 391 to 465 of region D and hypervariable region E of the capsid VP1 protein of 15 FCV 797 
isolates obtained within this study (on top, shaded areas), of 4 FCV isolates associated with VSD 798 
(indicated with VS-FCV) and of nine other published FCV isolates are aligned to FCV-F9 (top 799 
sequence in the alignment). b. Residues 391 to 465 (top) and 480 to 550 (bottom) of region D and 800 
hypervariable region E of the capsid VP1 protein of the FCV isolates of cases, in-contact cats and 801 
non-contact cats in shelter 1 (shaded areas) and of 4 FCV isolates associated with VSD (indicated 802 
with VS-FCV) are aligned to FCV-F9 (top sequence in the alignment). GenBank accession numbers 803 
are shown in parentheses. Colored amino acids correspond to non-synonymous mutations in the RNA 804 
sequence compared to the FCV-F9 reference strain. Arrows indicate mutations previously described in 805 
FCV isolates associated with VSD, some of which were also observed in the FCV isolates from this 806 
study (V430T, cases 1 - 5 and in-contact cats, and cases 6, 9, 10 and 11 (Foley et al., 2006); N443S, 807 
cases 1 - 5 and in-contact cats (Abd-Eldaim et al., 2005); G450D, cases 7 and 8 (Prikhodko et al., 808 
2014); D452E, cases 7,8 and 11 (Foley et al., 2006); V456M, case 6 (Prikhodko et al., 2014)). 809 
Asterisks indicate amino acid positions associated with selection of the neutralization-resistant virus 810 
mutants (Tohya et al., 1997) and the black bar marks a linear B-cell epitope mapped by Radford et al. 811 
(Radford et al., 1999).  The   “+”   signs   indicate   the  positions  of   the  VP1   residues   involved   in   putative  812 
contact between VP1 and fJAM-A (Bhella and Goodfellow, 2011). The triangles indicate amino acid 813 
substitutions present in all FCV isolates of the affected kittens, the queen and in-contact cats and 814 
absent in the FCV isolates of the non-contact cats in shelter 1. The three question marks in the 815 
sequence of case 2 at positions 441, 449 and 488 represent amino acid uncertainties K/N, N/T and 816 
T/I, respectively.  817 
     Willi et al., 09.10.15 
 1 
Table 1: Results for FCV, FHV-1, FeLV and FIV of symptomatic cats and of healthy in-contact cats. Positive results are shown in bold.  1 
Location Cat Samples collected1,2 Date of sampling FCV RT-qPCR FHV-1 PCR6 FeLV6 FIV6 
Shelter 1 Case 1  OC, blood Nov 2011 positive3 negative negative7 negative9 
 Case 2 OC, blood Nov 2011 positive3 negative negative7 negative9 
 Case 3 OC, blood Nov 2011 positive3 negative negative7 negative9 
 Case 4 OC, blood Nov 2011 positive3 negative negative7 negative9 
 Case 5 OC, blood Nov 2011 positive3 negative negative7 negative9 
 Queen OC Nov 2011 positive nt nt nt 
 In-contact cat 1 OC Nov 2011 positive nt nt nt 
 In-contact cat 2 OC Nov 2011 positive nt nt nt 
 In-contact cat 3 OC Nov 2011 positive nt nt nt 
Clinic 1 Case 6 OC, blood Jul 2012 positive3,4 negative nt nt 
  Edema and pustule fluid Jul 2012 positive nt nt nt 
Shelter 2 Case 7 OC, blood Aug 2012 positive3 nt negative7 negative9 
  OC/NS/CS Oct 2012 positive negative negative8 negative10 
 Case 8 OC/NS/CS Oct 2012 positive negative negative8 negative10 
Shelter 2 Case 9 OC/NS/CS Jan 2013 positive negative negative8 negative10 
 Case 10 OC/NS/CS Jan 2013 positive negative negative8 positive10 
Clinic 2 Case 11 OC/NS/CS, blood April 2014 positive4,5 negative negative7 negative9 
  Mucosa, skin and liver May 2014 positive nt nt nt 
1 OC, oropharyngeal cytobrush, 2 OC/NS/CS, pooled material from oropharyngeal cytobrush, nasal and conjunctival swabs, 3 FCV RT-qPCR positive in the OC, 4 FCV RT-qPCR 2 
positive in blood, 5 FCV RT-qPCR positive in the OC/NS/CS, 6 nt, not tested; 7 result of FeLV ELISA from blood, 8 result of FeLV RT-qPCR from OC/NS/CS, 9 result of FIV ELISA 3 
from blood, 10 result of FIV RT-qPCR from OC/NS/CS (for details see Materials and Methods).  4 
Table
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Table 2: Virus neutralization titers of FCV isolates from symptomatic cats and from healthy in-contact cats. Maximal neutralization titers 5 
for each FCV isolate are shown in bold. Vaccination status and vaccine strain used in the cats are indicated. Homologous antibody titers 6 
of antisera S1 - S8 are shown at the bottom. 7 
1 The homologous titers of the antisera were calculated by testing them for neutralization against the relevant FCV vaccine strain (FCV-F9, FCV-255, FCV-431 or FCV-G1), 2 V, 8 
vaccinated, NV, not vaccinated, 3 Case 6 was regularly vaccinated against FCV, FHV-1 and panleukopenia until 2009, 4 Cases 9 and 10 received one shot of a FCV, FHV-1, 9 
panleukopenia vaccine 10 days before the first symptoms of severe FCV infection occurred (see result section, cases 9 and 10), 5 Case 11 was vaccinated annually against FCV, 10 
FHV-1, panleukopenia and FeLV between 2007 -2013, 6 Virus neutralizing antibody titers of antisera S1 – S8 produced with FCV-G1 (S1, S2), FCV-431 (S3, S4), FCV-255 (S5, 11 
S6) and FCV-F9 (S7, S8), respectively, with the FCV strains isolated from each cat (for details see Material and Methods), 7 Neutralization titers <15 were not determined in these 12 
samples because of the limited volume of antiserum S3. 13 
Location 
 
Cat Vaccination 
status2 
Vaccine strain S1 6 
G1 
S2 6 
G1 
S3 6 
431 
S4 6 
431 
S5 6 
255 
S6 6 
255 
S7 6 
F9 
S8 6 
F9 
Shelter 1 Case 1 NV  <5 5 <5 15 5 135 <5 <5 
 Case 3 NV  <5 5 <5 15 5 405 <5 <5 
 Case 4 NV  <5 5 5 15 5 405 <5 <5 
 Case 5 NV  <5 5 5 15 15 135 <5 <5 
  In-contact cat 1 NV  <5 5 <5 15 15 135 <5 <5 
 In-contact cat 2 NV  <5 5 <5 15 5 405 <5 <5 
 In contact cat 3 NV  <5 5 <5 15 15 405 <5 <5 
Clinic 1 Case 6 V 3 FCV-F9 5 45 5 15 5 5 <5 15 
Shelter 2 Case 7 NV  <5 135 15 135 <5 <5 <5 <5 
 Case 8 NV  5 45 45 135 15 15 5 5 
 Case 9 V4 FCV-F9 <5 15 5 <5 <5 5 <5 <5 
 Case 10  V4 FCV-F9 <5 15 <15 7 5 <5 <5 <5 <5 
Clinic 2 Case 11 V5 FCV-F9 <5 405 <15 7 45 15 135 <5 <5 
Homologous antibody titres1    1215 1215 1215 3645 645 1215 405 405 
Figure 1 a 
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